Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: mometasone furoate Clear all
Completed Phase 2 Interventional Results available

Mandibular Advancement vs Home Treatment for Primary Snoring

NCT05756647
View directory record Official record
Conditions
Snoring
Interventions
Interventional Arm, Conservative treatment Arm
Device · Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

NCT02045875
View directory record Official record
Conditions
Asthma
Interventions
Dulera
Drug
Lead sponsor
Asthma Management Systems
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia

NCT02228720
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Propel Nova Sinus Implant
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

NCT05035654
View directory record Official record
Conditions
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions
LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2)
Drug
Lead sponsor
Lyra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Carlsbad, California • La Mesa, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 15, 2026, 10:43 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

NCT03599271
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Drug-Coated Device, Control Device
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 15, 2026, 10:43 AM EDT
Not listed Phase 1 Interventional

Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury

NCT01353599
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Mometasone furoate
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

NCT01253577
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Sinus Stent with drug coating, Non Coated Sinus Stent
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Fresno, California • Colorado Springs, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

NCT01920893
View directory record Official record
Conditions
Nasal Polyps
Interventions
Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 15, 2026, 10:43 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

NCT05626621
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray, Mometasone Nasal Irrigation (1 mg capsule), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

NCT01401465
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide, mometasone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
Huntington Beach, California • Mission Veijo, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Sep 15, 2026, 10:43 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

NCT02554786
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

NCT00662883
View directory record Official record
Conditions
Healthy
Interventions
PMI-150 (intranasal ketamine HCl); mometasone furoate
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 15, 2026, 10:43 AM EDT
Withdrawn Phase 4 Interventional

Use of Mometasone Eluting Stent in Choanal Atresia

NCT03605537
View directory record Official record
Conditions
Choanal Atresia
Interventions
Drug-eluting Stent Mometasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 4 Interventional

Onset and Duration of Mometasone by Oscillometry and Spirometry

NCT01635088
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate 220, KoKo Spirometry, Mometasone furoate 440, Oscillometry
Drug · Device
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 15, 2026, 10:43 AM EDT
Completed No phase listed Observational

Replication of the P04334 Asthma Trial in Healthcare Claims Data

NCT04892758
View directory record Official record
Conditions
Asthma
Interventions
Formoterol fumarate 10 mcg, Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 120 Years
Enrollment
10,288 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery

NCT02687438
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Steroid-releasing sinus implant, Post-op standard of care
Device · Other
Lead sponsor
ENT and Allergy Associates, LLP
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Lake Success, New York • New York, New York • Port Jefferson, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 15, 2026, 10:43 AM EDT